Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy
Joint Authors
Miranda-Filloy, José A.
González-Juanatey, Carlos
Gonzalez-Gay, Miguel A.
Vazquez-Rodriguez, Tomas R.
Gomez-Acebo, Ines
Testa, Ana
Garcia-Porrua, Carlos
Sanchez-Andrade, Amalia
Llorca, Javier
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-07-31
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
To determine whether treatment with the anti-TNF-alpha blocker adalimumab yields persistent improvement of endothelial function and prevents from morphological progression of subclinical atherosclerosis in patients with rheumatoid arthritis (RA) refractory to conventional therapy, a series of 34 consecutive RA patients, attending hospital outpatient clinics and who were switched from disease modifying antirheumatic drug therapy to anti-TNF-alpha-adalimumab treatment because of severe disease, were assessed by ultrasonography techniques before the onset of adalimumab therapy (at day 0) and then at day 14 and at month 12.
Values of flow-mediated endothelium-dependent vasodilatation at day 14 and at month 12 were significantly higher (mean ± standard deviation (SD): 6.1±3.9%; median: 5.7% at day 14, and mean ± SD: 7.4±2.8%; median: 6.9% at month 12) than those obtained at day 0 (mean: 4.5±4.0%; median: 3.6%; P=0.03 and P<0.001, resp.).
Endothelium-independent vasodilatation results did not significantly change compared with those obtained at day 0.
No significant differences were observed when carotid artery intima-media wall thickness values obtained at month 12 (mean ± SD: 0.69±0.21 mm) were compared with those found at day 0 (0.65±0.16 mm) (P=0.3).
In conclusion, anti-TNF-alpha-adalimumab therapy has beneficial effects on the development of the subclinical atherosclerosis disease in RA.
American Psychological Association (APA)
González-Juanatey, Carlos& Vazquez-Rodriguez, Tomas R.& Miranda-Filloy, José A.& Gomez-Acebo, Ines& Testa, Ana& Garcia-Porrua, Carlos…[et al.]. 2012. Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy. Mediators of Inflammation،Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-1029427
Modern Language Association (MLA)
González-Juanatey, Carlos…[et al.]. Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy. Mediators of Inflammation No. 2012 (2012), pp.1-8.
https://search.emarefa.net/detail/BIM-1029427
American Medical Association (AMA)
González-Juanatey, Carlos& Vazquez-Rodriguez, Tomas R.& Miranda-Filloy, José A.& Gomez-Acebo, Ines& Testa, Ana& Garcia-Porrua, Carlos…[et al.]. Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy. Mediators of Inflammation. 2012. Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-1029427
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1029427